On Demand Education

Updates in Screening and Surveillance for Barrett’s Esophagus

We have become excellent at treating Barrett’s esophagus (BE) related neoplasia. But to reduce the instance of esophageal adenocarcinoma (EAC) we need to increase the population under surveillance and leverage risk stratification tools to personalize the management of non-dysplastic BE.

Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy Northwestern University

Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test: An Interview with the Lead Author of DecisionDx-SCC’s Validation Study

Maui Derm DecisionDx-SCC Product Theater: Identifying the Risk of Metastasis in cSCC Patients with One or More Risk Factors

AHNS DecisionDx–SCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients

Mohs Certifying Exam Review 2022

Brent Moody, MD, FACP, FAAD, Michael B. Morgan, MD,

DermPath on Demand: Utility of Gene Expression Profiling in Melanocytic Lesions

Clay Cockerell, M.D.


Learn About Castle’s Comprehensive Diagnostic Offering

Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.

Matthew Goldberg, MD

DecisionDx-Melanoma: Predicting Individualized Risk of Recurrence

31-GEP: Sentinel Lymph Node Biopsy Guidance

John Vetto, MD, FACS


Castle Biosciences - Revolutionizing Gene Expression Profiling in Clinical Management of Dermatologic Cancers

Aarron Farberg, MD, FAAD Baylor University Medical Center, Dallas TX


Use of a Genomic-based Prognostic Tool to Inform Clinical Decisions for Patients with Cutaneous Melanoma

This activity is designed to address the following core and team competencies: Patient Care, Medical Knowledge, Practice-based learning and improvement, Interprofessional Collaboration, and Roles & Responsibilities.

Shannon Trotter, DO, Oakview Dermatology, Joseph Michael Guenther, MD, St. Elizabeth Physicians

CME/CE: (Credit Expiration Date: July 31st, 2021)

Incorporating Prognostic Gene Expression Profiling in the Management of Skin Cancer

Sep 2021

Drs. Trotter and Sligh hosted a live Q&A session on the content discussed in this webinar. Register for free to be part of the webinar.

This activity has been developed to meet the educational needs of dermatologists, nurse practitioners, physician assistants, and staff who are dedicated to the management of patients with cutaneous melanoma and cutaneous squamous cell carcinoma

Shannon Trotter, DO, Oakview Dermatology, James Sligh, MD, PhD, Bay Pines VA Medical Center

CME/CE: (1.0 AMA PRA Category 1 Credit(s))